Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 472 Jan 1 – Oct 24, 2026
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| E EnteroBiotixCompany profile Develops full-spectrum microbiome therapeutics for gastrointestinal diseases including IBS Develops full-spectrum microbiome therapeutics for gastrointestinal diseases including IBS | £19M | Series B | Biotech | United Kingdom | Investors | |
| GP General ProximityCompany profile Develops induced proximity medicines targeting undruggable proteins across oncology and cardiometabolic disease Develops induced proximity medicines targeting undruggable proteins across oncology and cardiometabolic disease | $20M | StrategicUndisclosed | Biotech | United States | Investors | |
| OB Oberland BiotechCompany profile Develops and trades nutritional supplements and food products internationally Develops and trades nutritional supplements and food products internationally | CHF 2.5M | Seed | Biotech | Switzerland | Investors | |
| M Decodes cellular networks to advance human health | $20M | Undisclosed | Biotech | Sweden | Investors | |
| IH Develops technology and services for clinical research. | $77M | Series CSeries C+ | Biotech, Healthtech | United States | Investors | |
| A AxoftCompany profile Develops implantable Brain-Computer Interfaces (iBCIs) for neurological disorders Develops implantable Brain-Computer Interfaces (iBCIs) for neurological disorders | $55M | Series A | Biotech, Healthtech | United States | Investors | |
| VB Vivacta BiotechnologyCompany profile Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases Develops in vivo CAR-T cell therapies for cancer and autoimmune diseases | $50M | Series A+Series A | Biotech | China | Investors | |
| F Develops optogenetic control for industrial-scale precision fermentation | $2M | Seed | Biotech | United States | Investors | |
| LP Lighthouse PharmaceuticalsCompany profile Develops novel small-molecule therapies for neurodegenerative and inflammatory diseases Develops novel small-molecule therapies for neurodegenerative and inflammatory diseases | $12M | Series A | Biotech | United States | Investors | |
| P Develops intracoronary liquid biopsy for cardiovascular disease | $5M | Undisclosed | Biotech | United Kingdom | Investors Undisclosed |
Active investors in this selection
All investors →Ranked by rounds participated in · From Jan 1, 2026
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.